Literature DB >> 12206308

High-level expression of the C-terminal hydrophobic region of HCV E2 protein ectodomain in E. coli.

Jing Liu1, Yuying Kong, Lixin Zhu, Yuan Wang, Guangdi Li.   

Abstract

High-level expression of hepatitis C virus (HCV) E2 protein fragments encompassing its C-terminal hydrophobic region (downstream of aa 661) in Escherichia coli has been proven difficult. The extreme hydrophobicity of this region has been suspected to be detrimental to the host. In this work, we found that the C-terminal region (downstream of aa 565) of E2 ectodomain interfered with full-length expression of E2 fragments in E. coli. Nonetheless, when the central region (aa 484-622) of E2 was deleted, full-length protein was efficiently produced. C-terminal region aa 567-700 could not be efficiently expressed individually or as mouse dihydrofolate reductase (DHFR) fusion protein. However, a mutant that emerged in the cloning process was able to express full-length DHFR fusion protein. Sequencing analysis reveals the mutation to be a short frame-shift around the fusion junction, altering aa 568-571 of E2. C-terminal region of E2 ectodomain (aa 567-730) carrying this mutation was successfully expressed as hexa-histidine-tagged protein to a high level. The protein was highly insoluble and was purified under denaturing conditions. The purified protein displayed HCV E2-specific antigenicity in Western blot and specific rabbit antiserum was raised against it. These results demonstrate that hydrophobicity of the C-terminal region of E2 ectodomain is not harmful to E. coli host and has no dominative adverse effect on its bacterial expression. Other nucleotide and/or amino acid sequence properties seem to play a more important role. This finding opens up new possibilities for the development of novel bacterially-derived E2 proteins for research and clinical applications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12206308     DOI: 10.1023/a:1020136022896

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  21 in total

1.  Evaluation of hepatitis C virus envelope proteins expressed in E. coli and insect cells for use as tools for antibody screening.

Authors:  P Hüssy; H Faust; J C Wagner; G Schmid; J Mous; H Jacobsen
Journal:  J Hepatol       Date:  1997-06       Impact factor: 25.083

2.  Immunological evaluation of Escherichia coli-derived hepatitis C virus second envelope protein (E2) variants.

Authors:  S Dueñas-Carrera; A Viña; H E Garay; O Reyes; L Alvarez-Lajonchere; I Guerra; L J González; J Morales
Journal:  J Pept Res       Date:  2001-09

3.  Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Authors:  M Flint; C Maidens; L D Loomis-Price; C Shotton; J Dubuisson; P Monk; A Higginbottom; S Levy; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

5.  A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.

Authors:  D Rosa; S Campagnoli; C Moretto; E Guenzi; L Cousens; M Chin; C Dong; A J Weiner; J Y Lau; Q L Choo; D Chien; P Pileri; M Houghton; S Abrignani
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

6.  Anti-HCV envelope prevalence in blood donors from Baden-Württemberg.

Authors:  M da Silva Cardoso; D Sturm; K Koerner; T Dengler; M Kerowgan; B Kubanek
Journal:  Ann Hematol       Date:  1997-03       Impact factor: 3.673

7.  Prevalence, genotypes, and an isolate (HC-C2) of hepatitis C virus in Chinese patients with liver disease.

Authors:  Y Wang; H Okamoto; F Tsuda; R Nagayama; Q M Tao; S Mishiro
Journal:  J Med Virol       Date:  1993-07       Impact factor: 2.327

8.  Vaccination of chimpanzees against infection by the hepatitis C virus.

Authors:  Q L Choo; G Kuo; R Ralston; A Weiner; D Chien; G Van Nest; J Han; K Berger; K Thudium; C Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

9.  Expression of MBP-HCV NS1/E2 fusion protein in E. coli and detection of anti-NS1/E2 antibody in type C chronic liver disease.

Authors:  E Mita; N Hayashi; K Ueda; A Kasahara; H Fusamoto; A Takamizawa; K Matsubara; H Okayama; T Kamada
Journal:  Biochem Biophys Res Commun       Date:  1992-03-31       Impact factor: 3.575

10.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more
  1 in total

1.  Purification and application of C-terminally truncated hepatitis C virus E1 proteins expressed in Escherichia coli.

Authors:  Jing Liu; Li-Xin Zhu; Yu-Ying Kong; Guang-Di Li; Yuan Wang
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.